Awakn Life Sciences Bristol Clinic Receives Care Quality Commission Approval to Begin Treatments in the UK's First Medical Psychedelic Clinic
Toronto, Ontario--(Newsfile Corp. - October 20, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today that Awakn Clinics Bristol has received Care Quality Commission's (CQC) formal approval to begin treatments. "This is a very exciting moment for Awakn Life Sciences, but more importantly for anyone suffering from addiction or...
2021-10-20 7:30 AM EDT
Awakn Life Sciences to Present at the KCSA Psychedelics Virtual Investor Conference on October 13th
Toronto, Ontario--(Newsfile Corp. - October 8, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Anthony Tennyson, CEO of Awakn Life Sciences, will participate in the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021. Anthony Tennyson will present live on Wednesday,...
2021-10-08 4:30 PM EDT
Awakn Life Sciences Announces Closing of Acquisition of Leading Ketamine-Assisted Psychotherapy Clinic in Norway
Toronto, Ontario--(Newsfile Corp. - October 5, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, is pleased to announce the closing of its acquisition of Axonklinikken AS ("Axon"), a leading ketamine-assisted psychotherapy clinic in Norway, as previously announced on September 16, 2021. Upon the completion of the...
2021-10-05 7:30 AM EDT
Awakn Life Sciences Acquires Exclusive Rights to MDMA Research from Imperial College London
Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - Awakn Life Sciences Corp., (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn) a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, announced today that it has acquired the exclusive rights to the data from the phase IIa Bristol Imperial MDMA in Alcoholism Study (BIMA) from Imperial College London, which has one of the world's leading psychedelics research centers. BIMA was an Open-label safety,...
2021-09-23 7:30 AM EDT
Awakn Life Sciences to Present at the Oppenheimer and Maxim Group September Investor Conferences
Toronto, Ontario--(Newsfile Corp. - September 20, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, will present in the following upcoming September investor conferences. Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Date: Monday, September 20th - Thursday, September 23rd...
2021-09-20 2:00 PM EDT
Awakn Life Sciences to Acquire Leading Ketamine-Assisted Psychotherapy Clinic in Norway
Toronto, Ontario--(Newsfile Corp. - September 16, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a biotechnology company developing and delivering psychedelic medicine to treat addiction, is pleased to announce that it has signed a binding share exchange agreement to acquire a 100% interest in Axonklinikken AS ("Axon"), a leading ketamine-assisted psychotherapy clinic in Norway. As part of the transaction Axon will be renamed 'Awakn Oslo...
2021-09-16 7:53 AM EDT
Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business Highlights
Toronto, Ontario--(Newsfile Corp. - September 15, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today is reporting its financial results and business highlights for the three and six months ended July 31, 2021. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise...
2021-09-15 7:30 AM EDT
Awakn Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Toronto, Ontario--(Newsfile Corp. - September 9, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat addiction, announced today that Anthony Tennyson, Chief Executive Officer, will present in the upcoming H. C. Wainwright conference. Anthony Tennyson's, Chief Executive Officer of Awakn Life Sciences, corporate presentation will be available on-demand...
2021-09-09 7:30 AM EDT
Awakn Life Sciences Announces DTC Eligibility
Toronto, Ontario--(Newsfile Corp. - September 2, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic medicines to treat Addiction, announces that it has received Depository Trust & Clearing Corporation ("DTC") eligibility. DTC eligibility allows Awakn's shares to be electronically cleared and settled, which will streamline the process of trading, enhance liquidity, and provide direct access to...
2021-09-02 7:30 AM EDT
Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan
Toronto, Ontario--(Newsfile Corp. - August 24, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn), a biotechnology company developing and delivering psychedelic medicine to better treat Addiction, announced today that it has received ethical committee approval and has initiated recruitment for the first-ever study investigating ketamine in gambling addiction. The study will be led by Celia Morgan, Ph.D., Professor of Psychopharmacology at the University of Exeter,...
2021-08-24 7:30 AM EDT
Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under the Symbol 'AWKNF' on August 12th
Toronto, Ontario--(Newsfile Corp. - August 12, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, is pleased to announce that it has qualified to trade on the OTCQB® Venture Market ("OTCQB") under the ticker symbol "AWKNF" today, Tuesday, August 12, 2021. The OTCQB is the venture tier of OTC Markets on which 11,000 U.S. and global securities trade....
2021-08-12 6:30 AM EDT
Awakn Life Sciences to Present at the Canaccord Genuity 41st Annual Virtual Growth Conference
Toronto, Ontario--(Newsfile Corp. - August 9, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, will present in Canaccord Genuity's 41st Annual Growth Conference on Tuesday, August 10, 2021. Canaccord Genuity's 41st Annual Growth Conference Date: Tuesday, August 10th Time: 9:30 -...
2021-08-09 10:07 AM EDT
Awakn Life Sciences Announces Its Second Location in the UK for "Awakn Clinics London," Providing Treatment to the Largest City in the UK
Toronto, Ontario--(Newsfile Corp. - August 4, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today announced the signing of its 10-year lease to open Awakn Clinics London, a psychedelic-focused therapy cente
2021-08-04 8:06 AM EDT
Awakn Life Sciences to Commence Trading on the OTC Market on July 26, 2021 Under the Symbol 'AWKNF'
Toronto, Ontario--(Newsfile Corp. - July 26, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat addiction, today announced approval from the Financial Regulatory Authority ("FINRA") for its shares to commence trading on the OTC Market (the "OTC") in the United States under the symbol "AWKNF" effective today, July 26, 2021. Awakn will continue to trade on the...
2021-07-26 8:15 AM EDT
Awakn Life Sciences Announces the Addition of Renowned Substance Addiction Researcher Professor Barbara Mason to Its Clinical Advisory Board
Toronto, Ontario--(Newsfile Corp. - July 22, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering medicines to better treat Addiction, is delighted to announce today that Professor Barbara Mason has joined as an advisor on Awakn's Clinical Advisory Board. The board, which is chaired by Prof. David Nutt is focused on bringing new therapeutic paradigms to market as quickly as possible. Prof. Mason's experience in the...
2021-07-22 8:00 AM EDT
Awakn Life Sciences Initiates Research Program to Further Develop Ketamine-Assisted Therapies for Treating Addiction
Toronto, Ontario--(Newsfile Corp. - July 14, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat addiction, announced that it will undertake a program of clinical research designed to demonstrate the effectiveness for ketamine-assisted psychotherapy against multiple addictions. Awakn estimates that between 15% and 20% of the global adult population1, or between 840 million and...
2021-07-14 7:30 AM EDT
Awakn Establishes Separate Preclinical and Clinical Expert Advisory Boards to Optimize Delivery of Its Expanding Development Pipeline
Toronto, Ontario--(Newsfile Corp. - July 7, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, announced today that it will establish separate preclinical and clinical expert advisory boards to add to its existing Scientific Advisory Board's capabilities, to optimize delivery of its expanding development pipeline. Both advisory boards will be led by Prof. David Nutt,...
2021-07-07 8:15 AM EDT
Awakn Life Sciences Files Patent Applications in U.S. for AWKN001 and AWKN002, Two Next-Generation New Chemical Entities [NCEs] to Treat a Broad Range of Addiction Indications
Toronto, Ontario--(Newsfile Corp. - June 28, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today announced the filing of patent applications in the U.S. for two next-generation novel MDMA-derived new chemical entities, AWKN001 and AWKN002, further strengthening Awakn's intellectual property portfolio and pipeline for the treatment of a broad range of Addictions...
2021-06-28 7:30 AM EDT
Awakn Life Sciences Appoints Addiction Expert Prof. David Nutt as Chief Research Officer
Toronto, Ontario--(Newsfile Corp. - June 24, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering psychedelic medicine to treat Addiction, announced today that globally renowned neuroscientist and addiction researcher, Prof. David Nutt, has joined its executive team as Chief Research Officer. This appointment is driven by the expansion of Awakn's psychedelic drug and therapy development pipeline targeting Addiction....
2021-06-24 7:00 AM EDT
Awakn Life Sciences to Commence Trading on the NEO Exchange Under the Symbol 'AWKN'
Toronto, Ontario--(Newsfile Corp. - June 23, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) ("Awakn" or the "Company") a biotechnology company with clinical operations developing, and delivering psychedelic medicines to treat Addiction, is pleased to announce it will begin trading today, June 23, 2021, on the NEO Exchange Inc. (the "NEO") under the symbol "AWKN". "Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic...
2021-06-23 7:30 AM EDT